

Maywufa Company Ltd. and Subsidiaries

**Consolidated Financial Statements for the
Nine Months Ended September 30, 2025 and 2024 and
Independent Auditors' Review Report**

INDEPENDENT AUDITORS' REVIEW REPORT

The Board of Directors and Shareholders
Maywufa Company Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Maywufa Company and its subsidiaries (collectively, the "Group") as of September 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three months ended September 30, 2025 and 2024 and for the nine months ended September 30, 2025 and 2024, the consolidated statements of changes in equity and cash flows for the nine months then ended, and the related notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the "consolidated financial statements"). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews and the report of other auditors (refer to the other matter paragraph), nothing has come to our attention that caused us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as of September 30, 2025 and 2024, its consolidated financial performance for the three months ended September 30, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the nine months ended September 30, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Other Matter

We did not review the financial statements of PhytoHealth Corporation, AmCad BioMed Corporation and Broadsound Corporation accounted for using the equity method as of September 30, 2025 and 2024, but such statements were reviewed by other auditors. Our conclusion, insofar as it relates to the amounts of investments accounted for using the equity method and other comprehensive income included in the consolidated financial statements for these investees, is based solely on the reports of other auditors. According to the reports of other auditors as of September 30, 2025 and 2024, the amounts of the investments accounted for using the equity method of Maywufa Group were NT\$507,108 thousand and NT\$515,729 thousand, respectively, representing 16% and 17%, respectively, of the consolidated total assets; for the nine months ended September 30, 2025 and 2024, the amounts of investments accounted for using the equity method - losses recognized by Maywufa Group were NT\$12,533 thousand and NT\$14,230 thousand, respectively, representing (7%) and (8%), respectively, of the consolidated total profit before income tax.

The engagement partners on the reviews resulting in this independent auditors' review report are Hai-Yueh Huang and Cheng-Chuan Yu.

Deloitte & Touche
Taipei, Taiwan
Republic of China

November 12, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (In Thousands of New Taiwan Dollars)

ASSETS	September 30, 2025		December 31, 2024		September 30, 2024	
	Amount	%	Amount	%	Amount	%
CURRENT ASSETS						
Cash and cash equivalents (Note 6)	\$ 123,556	4	\$ 175,367	6	\$ 169,783	6
Financial assets at fair value through profit or loss (Note 7)	-	-	12,000	-	-	-
Notes receivable (Notes 8 and 22)	12,533	-	11,145	-	11,738	-
Accounts receivable (Notes 8, 22 and 29)	276,640	9	239,286	8	248,010	8
Other receivables (Notes 8 and 29)	2,374	-	1,889	-	2,515	-
Inventories (Note 9)	295,469	10	279,750	9	270,825	9
Prepayments	2,289	-	2,160	-	2,363	-
Other financial assets - current (Note 10)	396,626	13	418,120	13	370,160	12
Other current assets (Note 16)	1,245	-	380	-	1,019	-
Total current assets	<u>1,110,732</u>	<u>36</u>	<u>1,140,097</u>	<u>36</u>	<u>1,076,413</u>	<u>35</u>
NON-CURRENT ASSETS						
Financial assets at fair value through other comprehensive income - non-current (Note 12)	112,281	4	135,606	5	150,742	5
Investments accounted for using the equity method (Note 13)	509,451	17	512,968	16	518,081	17
Property, plant and equipment (Notes 14 and 30)	1,243,292	40	1,269,968	40	1,227,230	40
Right-of-use assets (Note 15)	7,784	-	4,255	-	4,699	-
Intangible assets	7,163	-	7,072	-	6,147	-
Deferred tax assets (Note 4)	38,064	1	31,669	1	33,653	1
Refundable deposits	5,521	-	5,163	-	5,036	-
Net defined benefit assets - non-current (Note 4)	72,244	2	71,508	2	60,017	2
Other non-current assets (Note 16)	385	-	-	-	-	-
Total non-current assets	<u>1,996,185</u>	<u>64</u>	<u>2,038,209</u>	<u>64</u>	<u>2,005,605</u>	<u>65</u>
TOTAL	<u>\$ 3,106,917</u>	<u>100</u>	<u>\$ 3,178,306</u>	<u>100</u>	<u>\$ 3,082,018</u>	<u>100</u>
LIABILITIES AND EQUITY						
CURRENT LIABILITIES						
Short-term borrowings (Note 17)	\$ -	-	\$ 35,000	1	\$ 35,000	1
Notes payable (Note 18)	17	-	10	-	84	-
Accounts payable (Notes 18 and 29)	76,927	2	96,398	3	83,104	3
Other payables (Notes 19 and 29)	259,469	8	249,975	8	284,567	9
Current tax liabilities (Note 4)	19,999	1	27,100	1	20,419	1
Lease liabilities - current (Note 15)	2,453	-	1,818	-	1,813	-
Other current liabilities	21,593	1	22,255	1	21,913	1
Total current liabilities	<u>380,458</u>	<u>12</u>	<u>432,556</u>	<u>14</u>	<u>446,900</u>	<u>15</u>
NON-CURRENT LIABILITIES						
Long-term borrowings (Notes 17 and 30)	634,464	21	634,464	20	558,938	18
Deferred tax liabilities (Note 4)	3	-	18	-	10	-
Lease liabilities - non-current (Note 15)	5,475	-	2,504	-	2,949	-
Guarantee deposits (Note 29)	1,945	-	1,945	-	1,945	-
Total non-current liabilities	<u>641,887</u>	<u>21</u>	<u>638,931</u>	<u>20</u>	<u>563,842</u>	<u>18</u>
Total liabilities	<u>1,022,345</u>	<u>33</u>	<u>1,071,487</u>	<u>34</u>	<u>1,010,742</u>	<u>33</u>
EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE PARENT (Note 21)						
Share capital - ordinary shares	1,329,152	43	1,329,152	42	1,329,152	43
Capital surplus	192,208	6	192,157	6	192,425	6
Retained earnings						
Legal reserve	233,894	8	214,672	6	214,672	7
Special reserve	62,362	2	89,821	3	89,821	3
Unappropriated earnings	352,503	11	343,379	11	295,422	10
Total retained earnings	648,759	21	647,872	20	599,915	20
Other equity	(85,547)	(3)	(62,362)	(2)	(50,216)	(2)
Total equity	<u>2,084,572</u>	<u>67</u>	<u>2,106,819</u>	<u>66</u>	<u>2,071,276</u>	<u>67</u>
TOTAL	<u>\$ 3,106,917</u>	<u>100</u>	<u>\$ 3,178,306</u>	<u>100</u>	<u>\$ 3,082,018</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated November 12, 2025)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME OR LOSS (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended September 30				For the Nine Months Ended September 30			
	2025		2024		2025		2024	
	Amount	%	Amount	%	Amount	%	Amount	%
OPERATING REVENUE (Notes 22 and 29)	\$ 372,251	100	\$ 351,804	100	\$ 1,169,240	100	\$ 1,109,779	100
OPERATING COSTS (Notes 9, 23 and 29)	<u>139,590</u>	<u>38</u>	<u>126,036</u>	<u>36</u>	<u>426,849</u>	<u>37</u>	<u>389,217</u>	<u>35</u>
GROSS PROFIT	<u>232,661</u>	<u>62</u>	<u>225,768</u>	<u>64</u>	<u>742,391</u>	<u>63</u>	<u>720,562</u>	<u>65</u>
OPERATING EXPENSES (Notes 20, 23 and 29)								
Selling and marketing expenses	159,899	43	153,286	44	490,810	42	468,661	42
General and administrative expenses	22,940	6	25,289	7	74,540	6	81,122	8
Expected credit impairment loss (gain on reversal) (Note 8)	<u>207</u>	<u>-</u>	<u>(50)</u>	<u>-</u>	<u>450</u>	<u>-</u>	<u>125</u>	<u>-</u>
Total operating expenses	<u>183,046</u>	<u>49</u>	<u>178,525</u>	<u>51</u>	<u>565,800</u>	<u>48</u>	<u>549,908</u>	<u>50</u>
PROFIT FROM OPERATIONS	<u>49,615</u>	<u>13</u>	<u>47,243</u>	<u>13</u>	<u>176,591</u>	<u>15</u>	<u>170,654</u>	<u>15</u>
NON-OPERATING INCOME AND EXPENSES (Note 23)								
Interest income	1,742	1	1,855	-	5,936	1	6,187	-
Other revenue (Note 29)	5,143	1	5,633	2	18,204	2	18,443	2
Other gains and losses	368	-	157	-	1,265	-	589	-
Interest expense	(2,134)	-	(1,195)	-	(6,071)	(1)	(1,271)	-
Share of profit or loss of associates (Note 13)	<u>(3,653)</u>	<u>(1)</u>	<u>(3,769)</u>	<u>(1)</u>	<u>(12,519)</u>	<u>(1)</u>	<u>(14,233)</u>	<u>(1)</u>
Total non-operating income and expenses	<u>1,466</u>	<u>1</u>	<u>2,681</u>	<u>1</u>	<u>6,815</u>	<u>1</u>	<u>9,715</u>	<u>1</u>
PROFIT BEFORE INCOME TAX	51,081	14	49,924	14	183,406	16	180,369	16
INCOME TAX EXPENSE (Notes 4 and 24)	<u>10,963</u>	<u>3</u>	<u>10,493</u>	<u>3</u>	<u>37,751</u>	<u>3</u>	<u>36,106</u>	<u>3</u>
NET PROFIT	<u>40,118</u>	<u>11</u>	<u>39,431</u>	<u>11</u>	<u>145,655</u>	<u>13</u>	<u>144,263</u>	<u>13</u>

(Continued)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME OR LOSS (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended September 30				For the Nine Months Ended September 30				
	2025		2024		2025		2024		
	Amount	%	Amount	%	Amount	%	Amount	%	
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 13 and 21)									
Items that will not be reclassified subsequently to profit or loss									
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	\$ 4,097	1	\$ 13,699	4	\$ 343	-	\$ 23,637	2	
Share of the other comprehensive income (loss) of associates accounted for using the equity method	1,010	-	(2,051)	(1)	(2,783)	-	9,660	1	
Items that may be reclassified subsequently to profit and loss									
Exchange differences on translation of financial statements of foreign operations	5,569	2	2,503	1	(6,016)	(1)	6,308	1	
Total other comprehensive income (loss) (net of income tax)	10,676	3	14,151	4	(8,456)	(1)	39,605	4	
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>\$ 50,794</u>	<u>14</u>	<u>\$ 53,582</u>	<u>15</u>	<u>\$ 137,199</u>	<u>12</u>	<u>\$ 183,868</u>	<u>17</u>	
NET INCOME ATTRIBUTABLE TO:									
Shareholders of the parent	<u>\$ 40,118</u>	<u>11</u>	<u>\$ 39,431</u>	<u>11</u>	<u>\$ 145,655</u>	<u>12</u>	<u>\$ 144,263</u>	<u>13</u>	
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:									
Shareholders of the parent	<u>\$ 50,794</u>	<u>14</u>	<u>\$ 53,582</u>	<u>15</u>	<u>\$ 137,199</u>	<u>12</u>	<u>\$ 183,868</u>	<u>17</u>	
EARNINGS PER SHARE (Note 25)									
Basic	<u>\$ 0.31</u>		<u>\$ 0.30</u>		<u>\$ 1.10</u>		<u>\$ 1.09</u>		
Diluted	<u>\$ 0.30</u>		<u>\$ 0.30</u>		<u>\$ 1.09</u>		<u>\$ 1.08</u>		

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated November 12, 2025)

(Concluded)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In Thousands of New Taiwan Dollars, Except Dividends Per Share)

	Share Capital (Note 21)	Capital Surplus (Note 21)	Retained Earnings (Note 21)			Other Equity (Note 21)		Total Equity
			Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of Financial Statements of Foreign Operations	Unrealized Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	
BALANCE ON JANUARY 1, 2024	\$ 1,329,152	\$ 189,320	\$ 197,797	\$ 106,162	\$ 304,546	\$ (18,070)	\$ (71,751)	\$ 2,037,156
Appropriation of 2023 earnings								
Legal reserve	-	-	16,875	-	(16,875)	-	-	-
Reversal of special reserve	-	-	-	(16,341)	16,341	-	-	-
Cash dividends - NT\$1.15 per share	-	-	-	-	(152,853)	-	-	(152,853)
Changes in capital surplus from investments in associates accounted for using the equity method (Notes 13 and 21)	-	3,105	-	-	-	-	-	3,105
Net profit for the nine months ended September 30, 2024	-	-	-	-	144,263	-	-	144,263
Other comprehensive income for the nine months ended September 30, 2024	-	-	-	-	-	6,308	33,297	39,605
Total comprehensive income or the nine months ended September 30, 2024	-	-	-	-	144,263	6,308	33,297	183,868
BALANCE ON SEPTEMBER 30, 2024	<u>\$ 1,329,152</u>	<u>\$ 192,425</u>	<u>\$ 214,672</u>	<u>\$ 89,821</u>	<u>\$ 295,422</u>	<u>\$ (11,762)</u>	<u>\$ (38,454)</u>	<u>\$ 2,071,276</u>
BALANCE ON JANUARY 1, 2025	\$ 1,329,152	\$ 192,157	\$ 214,672	\$ 89,821	\$ 343,379	\$ (13,199)	\$ (49,163)	\$ 2,106,819
Appropriation of 2024 earnings								
Legal reserve	-	-	19,222	-	(19,222)	-	-	-
Reversal of special reserve	-	-	-	(27,459)	27,459	-	-	-
Cash dividends - NT\$1.20 per share	-	-	-	-	(159,497)	-	-	(159,497)
Changes in capital surplus from investments in associates accounted for using the equity method (Notes 13 and 21)	-	51	-	-	-	-	-	51
Disposal of investments in equity instruments designated at fair value through other comprehensive income/disposal of investments in equity instruments designated at fair value through other comprehensive income by associates (Notes 12, 13 and 21)	-	-	-	-	14,729	-	(14,729)	-
Net profit for the nine months ended September 30, 2025	-	-	-	-	145,655	-	-	145,655
Other comprehensive loss for the nine months ended September 30, 2025	-	-	-	-	-	(6,016)	(2,440)	(8,456)
Total comprehensive income (loss) for the nine months ended September 30, 2025	-	-	-	-	145,655	(6,016)	(2,440)	137,199
BALANCE ON SEPTEMBER 30, 2025	<u>\$ 1,329,152</u>	<u>\$ 192,208</u>	<u>\$ 233,894</u>	<u>\$ 62,362</u>	<u>\$ 352,503</u>	<u>\$ (19,215)</u>	<u>\$ (66,332)</u>	<u>\$ 2,084,572</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated November 12, 2025)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Nine Months Ended September 30	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	\$ 183,406	\$ 180,369
Adjustments for:		
Depreciation expenses	38,940	22,785
Amortization expenses	1,908	1,379
Expected credit impairment loss	450	125
Net gain on fair value changes of financial assets at fair value through profit or loss	(281)	(60)
Interest expense	6,071	1,271
Interest income	(5,936)	(6,187)
Dividend income	(8,880)	(7,682)
Share of loss of associates	12,519	14,233
Write-down of inventories	-	2,427
Gain on lease modification	(6)	-
Changes in operating assets and liabilities:		
Financial assets at fair value through profit or loss	12,281	60
Notes receivable	(1,402)	10,893
Accounts receivable	(37,790)	(21,976)
Other receivables	(41)	649
Inventories	(15,924)	(15,163)
Prepayments	(135)	(1,030)
Other current assets	(865)	557
Net defined benefit assets	(736)	(275)
Notes payable	7	(41)
Accounts payable	(19,471)	(410)
Other payables	11,388	17,003
Other current liabilities	(634)	(3,697)
Cash generated from operations	174,869	195,230
Interest paid	(6,001)	(3,929)
Income tax paid	(51,262)	(48,849)
Net cash generated from operating activities	<u>117,606</u>	<u>142,452</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Disposal of financial assets at fair value through other comprehensive income	23,668	-
Acquisition of associates	(11,734)	(11,988)
Payments for property, plant and equipment	(12,687)	(171,559)
Increase in refundable deposits	(361)	-
Decrease in refundable deposits	-	300
Payments for intangible assets	(1,999)	(2,889)
Decrease in other financial assets	20,742	24,970
Increase in prepayments for equipment	(2,972)	(6,276)

(Continued)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Nine Months Ended September 30	
	2025	2024
Interest received	\$ 5,487	\$ 5,950
Dividends received	<u>8,880</u>	<u>7,682</u>
Net cash generated from (used in) investing activities	<u>29,024</u>	<u>(153,810)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Increase in short-term borrowings	-	35,000
Decrease in short-term borrowings	(35,000)	-
Proceeds from long-term borrowings	-	121,045
Repayment of the principal portion of lease liabilities	(1,346)	(3,940)
Dividends paid to owners of the Company	<u>(159,497)</u>	<u>(152,853)</u>
Net cash used in financing activities	<u>(195,843)</u>	<u>(748)</u>
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH AND CASH EQUIVALENTS HELD IN FOREIGN CURRENCIES		
	<u>(2,598)</u>	<u>3,408</u>
NET DECREASE IN CASH AND CASH EQUIVALENTS	(51,811)	(8,698)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	<u>175,367</u>	<u>178,481</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>\$ 123,556</u>	<u>\$ 169,783</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated November 12, 2025)

(Concluded)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

1. GENERAL INFORMATION

Maywufa Company Ltd. (the “Company”), along with the Company-controlled subsidiaries (collectively known as the “Group”), was incorporated in the Republic of China (ROC) in October 1976. The Company’s Chinese name was changed on April 30, 1998. The Company’s shares have been listed on the Taiwan Stock Exchange (TWSE) since September 17, 2001.

The main businesses of the Company are as follows:

- a. Manufacturing, processing and distribution of all kinds of hairdressing products (cleaning agents) soap, wholesale trading and agency.
- b. Manufacturing, processing and distribution of all kinds of cosmetics (except highly toxic), wholesale trading and agency, and trading of various department stores (the cosmetics manufacturing and processing department is limited to the main products of the factory).
- c. Distribution, wholesale and retail trading of various beauty products, health products and sports equipment.
- d. Retail and wholesale business of health food such as vitamin pills and oral liquid nutrients.
- e. Trading, wholesale and retail of medical drugs and medical equipment.
- f. Wholesale and retail sales of food, baby products and general food products enriched with vitamins, amino acids and minerals.
- g. Consulting and analytical advisory services for pharmacy management.
- h. Warehousing.

The consolidated financial statements are presented in the Company’s functional currency, the New Taiwan dollar.

2. APPROVAL OF FINANCIAL STATEMENTS

The consolidated financial statements were approved by the Company’s board of directors on November 12, 2025.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. Initial application of the amendments to the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) (collectively, the “IFRS Accounting Standards”) endorsed and issued into effect by the Financial Supervisory Commission (FSC)

The initial application of the IFRS Accounting Standards endorsed and issued into effect by the FSC did not have a material impact on the Group’s accounting policies.

- b. The IFRS Accounting Standards endorsed by the FSC for application starting from 2026

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
Annual Improvements to IFRS Accounting Standards - Volume 11	January 1, 2026
IFRS 17 “Insurance Contracts” (including the 2020 and 2021 amendments to IFRS 17)	January 1, 2023

As of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the other impacts of the above amended standards and interpretations on the Group’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

- c. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB (Note 1)
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note 2)
IFRS 19 “Subsidiaries without Public Accountability: Disclosures” (including the 2025 amendments to IFRS 19)	January 1, 2027

Note 1: Unless stated otherwise, the above IFRS Accounting Standards are effective for annual reporting periods beginning on or after their respective effective dates.

Note 2: On September 25, 2025, the FSC announced that IFRS 18 will take effect starting from January 1, 2028. Domestic entities could elect to apply IFRS 18 for an earlier period after the endorsement of IFRS 18 by the FSC.

IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 will supersede IAS 1 “Presentation of Financial Statements”. The main changes comprise:

- Items of income and expenses included in the statement of profit or loss shall be classified into the operating, investing, financing, income taxes and discontinued operations categories.
- The statement of profit or loss shall present totals and subtotals for operating profit or loss, profit or loss before financing and income taxes and profit or loss.
- Provides guidance to enhance the requirements of aggregation and disaggregation: The Group shall identify the assets, liabilities, equity, income, expenses and cash flows that arise from individual transactions or other events and shall classify and aggregate them into groups based on shared characteristics, so as to result in the presentation in the primary financial statements of line items that have at least one similar characteristic. The Group shall disaggregate items with dissimilar characteristics in the primary financial statements and in the notes. The Group labels items as “other” only if it cannot find a more informative label.

- Disclosures on Management-defined Performance Measures (MPMs): When in public communications outside financial statements and communicating to users of financial statements management's view of an aspect of the financial performance of the Group as a whole, the Group shall disclose related information about its MPMs in a single note to the financial statements, including the description of such measures, calculations, reconciliations to the subtotal or total specified by IFRS Accounting Standards and the income tax and non-controlling interests effects of related reconciliation items.

Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the other impacts of the above amended standards and interpretations on the Group's consolidated financial position and consolidated financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

a. Statement of compliance

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 "Interim Financial Reporting" as endorsed and issued into effect by the FSC. Disclosure information included in these interim consolidated financial statements is less than the disclosure information required in a complete set of annual consolidated financial statements.

b. Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value, and net defined benefit assets which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for the asset or liability.

c. Basis of consolidation

The consolidated financial statements incorporate the consolidated financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries). All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of the Company.

Refer to Notes 11 and 34, Tables 2 and 3 for detailed information on subsidiaries (including percentages of ownership and main businesses).

d. Other material accounting policies

Except for the following, please refer to the consolidated financial statements for the year ended December 31, 2024.

1) Retirement benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant plan amendments, settlements, or other significant one-off events.

2) Income tax expense

Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's pre-tax income the tax rate that would be applicable to expected total annual earnings.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Refer to the consolidated financial statements for the year ended December 31, 2024 for the material accounting judgments and key sources of estimation uncertainty.

6. CASH AND CASH EQUIVALENTS

	September 30, 2025	December 31, 2024	September 30, 2024
Cash on hand and petty cash	\$ 120	\$ 120	\$ 120
Checking accounts and demand deposits	48,404	118,967	50,008
Cash equivalents			
Time deposits with original maturities of 3 months or less	69,480	56,280	38,980
Call deposits with original maturities of 3 months or less	<u>5,552</u>	<u>-</u>	<u>80,675</u>
	<u>\$ 123,556</u>	<u>\$ 175,367</u>	<u>\$ 169,783</u>

The market interest rate intervals of bank deposits at the end of the reporting period were as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Bank deposits	0.05%-1.15%	0.002%-1.15%	0.05%-1.15%
Time deposits with original maturities of 3 months or less	1.225%-1.6%	1.225%	1.225%
Call deposits with original maturities of 3 months or less	1.2%	-	1.45%

7. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Current</u>			
Mutual funds	\$ <u>-</u>	\$ <u>12,000</u>	\$ <u>-</u>

8. NOTES RECEIVABLE, ACCOUNTS RECEIVABLE AND OTHER RECEIVABLES

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Notes receivable</u>			
At amortized cost			
Gross carrying amount	\$ 12,660	\$ 11,258	\$ 11,856
Less: Allowance for impairment loss	<u>(127)</u>	<u>(113)</u>	<u>(118)</u>
	<u>\$ 12,533</u>	<u>\$ 11,145</u>	<u>\$ 11,738</u>
<u>Accounts receivable</u>			
At amortized cost			
Gross carrying amount	\$ 279,481	\$ 241,702	\$ 250,462
Less: Allowance for impairment loss	<u>(2,876)</u>	<u>(2,440)</u>	<u>(2,529)</u>
	<u>276,605</u>	<u>239,262</u>	<u>247,933</u>
Accounts receivable from related parties (Note 29)	35	24	77
Less: Allowance for impairment loss	<u>-</u>	<u>-</u>	<u>-</u>
	<u>35</u>	<u>24</u>	<u>77</u>
	<u>\$ 276,640</u>	<u>\$ 239,286</u>	<u>\$ 248,010</u>
<u>Other receivables</u>			
Interest	\$ 719	\$ 270	\$ 491
Other	<u>59</u>	<u>50</u>	<u>37</u>
	778	320	528
Other receivables from related parties (Note 29)	<u>1,596</u>	<u>1,569</u>	<u>1,987</u>
	<u>\$ 2,374</u>	<u>\$ 1,889</u>	<u>\$ 2,515</u>

a. Notes receivable

The average credit period of sales of goods is 1-7 months. No interest is charged on notes receivable. In order to minimize credit risk, the management of the Group has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. The Group transacts with a large number of unrelated customers; therefore, credit risk is not highly concentrated. In this regard, the management believes the Group's credit risk is significantly reduced.

The Group measures the loss allowance for notes receivable at an amount equal to lifetime ECLs. The expected credit losses on notes receivable are estimated using a provision matrix by reference to the past default records of the customer and the customer's current financial position. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer base.

The Group writes off a note receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. For notes receivable that have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of notes receivable based on the Group's provision matrix:

September 30, 2025

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	-	-	-	-	
Gross carrying amount	\$ 12,660	\$ -	\$ -	\$ -	\$ -	\$ 12,660
Loss allowance (Lifetime ECLs)	<u>(127)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(127)</u>
Amortized cost	<u>\$ 12,533</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 12,533</u>

December 31, 2024

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	-	-	-	-	
Gross carrying amount	\$ 11,258	\$ -	\$ -	\$ -	\$ -	\$ 11,258
Loss allowance (Lifetime ECLs)	<u>(113)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(113)</u>
Amortized cost	<u>\$ 11,145</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 11,145</u>

September 30, 2024

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	-	-	-	-	
Gross carrying amount	\$ 11,856	\$ -	\$ -	\$ -	\$ -	\$ 11,856
Loss allowance (Lifetime ECLs)	<u>(118)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(118)</u>
Amortized cost	<u>\$ 11,738</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 11,738</u>

The movements of the loss allowance of notes receivable were as follows:

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ 113	\$ 227
Add: Provision	14	-
Less: Reversal	<u>-</u>	<u>(109)</u>
Balance on September 30	<u>\$ 127</u>	<u>\$ 118</u>

b. Accounts receivable

The average credit period of sales of goods is 1-7 months. No interest is charged on accounts receivable. In order to minimize credit risk, the management of the Group has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. The Group transacts with a large number of unrelated customers; therefore, credit risk is not highly concentrated. In this regard, the management believes the Group's credit risk was significantly reduced.

The Group measures the loss allowance for accounts receivable at an amount equal to lifetime ECLs. The expected credit losses on accounts receivable are estimated using a provision matrix prepared by reference to the past default records of the customer and the customer's current financial position. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer bases.

The Group writes off an account receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the debtor has been placed under liquidation, or when the trade receivables are over 180 days past due, whichever occurs earlier. For accounts receivable that have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of notes receivable based on the Group's provision matrix:

September 30, 2025

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	1%	1%	1%	1%	
Gross carrying amount	\$ 266,143	\$ 13,283	\$ 59	\$ 27	\$ 4	\$ 279,516
Loss allowance (Lifetime ECLs)	<u>(2,743)</u>	<u>(133)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,876)</u>
Amortized cost	<u>\$ 263,400</u>	<u>\$ 13,150</u>	<u>\$ 59</u>	<u>\$ 27</u>	<u>\$ 4</u>	<u>\$ 276,640</u>

December 31, 2024

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	1%-1.02%	-	-	-	
Gross carrying amount	\$ 222,500	\$ 19,226	\$ -	\$ -	\$ -	\$ 241,726
Loss allowance (Lifetime ECLs)	<u>(2,248)</u>	<u>(192)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,440)</u>
Amortized cost	<u>\$ 220,252</u>	<u>\$ 19,034</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 239,286</u>

September 30, 2024

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	1%	-	-	-	
Gross carrying amount	\$ 239,608	\$ 10,931	\$ -	\$ -	\$ -	\$ 250,539
Loss allowance (Lifetime ECLs)	<u>(2,420)</u>	<u>(109)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,529)</u>
Amortized cost	<u>\$ 237,188</u>	<u>\$ 10,822</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 248,010</u>

The movements of the loss allowance of accounts receivable were as follows:

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ 2,440	\$ 2,295
Add: Provision	<u>436</u>	<u>234</u>
Balance on September 30	<u>\$ 2,876</u>	<u>\$ 2,529</u>

c. Other receivables

The Group measures the loss allowance for other receivables at an amount equal to lifetime ECLs. The Group estimated the loss allowance by reference to the past default records of the customer and the customer's current financial position, and uses other publicly available financial information or its own trading records to rate the default risk of different receivables. As of September 30, 2025, December 31, 2024 and September 30, 2024, the management of the Group assessed other receivables with no expected credit losses.

9. INVENTORIES

	September 30, 2025	December 31, 2024	September 30, 2024
Commodities	\$ 78,662	\$ 68,181	\$ 80,347
Finished goods	123,095	125,605	91,017
Packaging materials	34,015	36,742	45,878
Raw materials	47,100	43,261	45,580
Work in progress	<u>12,597</u>	<u>5,961</u>	<u>8,003</u>
	<u>\$ 295,469</u>	<u>\$ 279,750</u>	<u>\$ 270,825</u>

The nature of the cost of goods sold were as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Cost of inventories sold	\$ 136,452	\$ 123,324	\$ 416,448	\$ 380,650
Write-down of inventories	-	(238)	-	2,427
Inventory obsolescence loss	3,138	2,951	10,401	6,141
(Gain) loss on physical inventory counts	<u>-</u>	<u>(1)</u>	<u>-</u>	<u>(1)</u>
	<u>\$ 139,590</u>	<u>\$ 126,036</u>	<u>\$ 426,849</u>	<u>\$ 389,217</u>

10. OTHER FINANCIAL ASSETS - CURRENT

	September 30, 2025	December 31, 2024	September 30, 2024
Time deposits with original maturities of more than 3 months	<u>\$ 396,626</u>	<u>\$ 418,120</u>	<u>\$ 370,160</u>

The market intervals of time deposits with original maturities of more than 3 months in the bank at the end of the reporting period were as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Time deposits	1.285%-1.690%	1.285%-1.690%	1.285%-1.690%

11. SUBSIDIARIES

Subsidiaries Included in the Consolidated Financial Statements

Investor	Investee	Nature of Activities	Percentage of Ownership (%)		
			September 30, 2025	December 31, 2024	September 30, 2024
Maywufa Company Ltd.	Maywufa Corporation (Samoa Maywufa)	Investment holdings	100.00	100.00	100.00
Maywufa Corporation (Samoa Maywufa)	Maywufa Hongkong Corporation Limited (Hong Kong Maywufa)	Investment holdings	100.00	100.00	100.00
Maywufa Hongkong Corporation Limited (Hong Kong Maywufa)	Maywufa Cosmetics (Shanghai) Co., Ltd. (Maywufa (Shanghai) Company)	Cosmetics and household goods wholesale	100.00	100.00	100.00

The main business risks of Samoa Maywufa and its subsidiaries are political risk and exchange rate risk due to changes in government regulations and cross-strait relations.

12. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Non-current</u>			
Domestic investments			
Listed shares	\$ 24,206	\$ 49,360	\$ 62,031
Unlisted shares	81,791	79,314	81,889
Foreign investments			
Unlisted shares	<u>6,284</u>	<u>6,932</u>	<u>6,822</u>
	<u>\$ 112,281</u>	<u>\$ 135,606</u>	<u>\$ 150,742</u>

Refer to Note 34 and Table 1 (Significant Marketable Securities Held) for information relating to the investments in the above table.

Refer to Note 21(e) for information relating to financial assets at fair value through other comprehensive income.

These investments in equity instruments are held for strategic purposes. Accordingly, the management elected to designate these investments in equity instruments as at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for purposes.

The Group adjusted the portion of the investment and sold certain listed ordinary shares at the fair value of \$23,668 thousand, resulting in an unrealized gain of \$7,368 thousand in the related other equity - financial assets at fair value through other comprehensive income and loss transferred to retained earnings for the nine months ended September 30, 2025.

13. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Listed company</u>			
PhytoHealth Corporation	\$ 453,127	\$ 451,990	\$ 457,101
AmCad BioMed Corporation	33,021	35,763	36,201
<u>Unlisted company</u>			
Broadsound Corporation	20,960	22,886	22,427
Lu Te Na Company Limited	<u>2,343</u>	<u>2,329</u>	<u>2,352</u>
	<u>\$ 509,451</u>	<u>\$ 512,968</u>	<u>\$ 518,081</u>

The Group's percentage of ownership and voting rights in associates as of the balance sheet date were as follows:

Name of Company	September 30, 2025	December 31, 2024	September 30, 2024
PhytoHealth Corporation	18.14%	17.69%	17.69%
AmCad BioMed Corporation	6.31%	6.31%	6.31%
Broadsound Corporation	10.00%	10.00%	10.00%
Lu Te Na Company Limited	35.00%	35.00%	35.00%

The Group holds less than 20% of the shares of PhytoHealth Corporation, AmCad BioMed Corporation, and Broadsound Corporation, but obtained some directors of these companies; therefore, it has significant influence over these companies, which are all accounted for using the equity method.

Refer to Note 34 and Table 2 (Information on Investees) for more information on the investees.

The Group's share of profit or loss in investments in associates accounted for using the equity method was as follows:

Name of Company	<u>For the Three Months Ended September 30</u>		<u>For the Nine Months Ended September 30</u>	
	2025	2024	2025	2024
PhytoHealth Corporation	\$ (2,375)	\$ (2,285)	\$ (7,995)	\$ (10,404)
AmCad BioMed Corporation	(633)	(1,186)	(2,612)	(2,929)
Broadsound Corporation	(645)	(298)	(1,926)	(897)
Lu Te Na Company Limited	<u>-</u>	<u>-</u>	<u>14</u>	<u>(3)</u>
	<u>\$ (3,653)</u>	<u>\$ (3,769)</u>	<u>\$ (12,519)</u>	<u>\$ (14,233)</u>

The liquidation of Lu Te Na Co. was approved in March 2025, and the dissolution registration has been completed with the municipal government. As of September 30, 2025, the liquidation has not yet been finalized.

The Group recognized of \$51 thousand and \$3,106 thousand in capital surplus for the changes in other equity of the associates in proportion to its shareholding as of September 30, 2025 and 2024, respectively.

The Group recognized \$7,361 thousand of equity instruments measured at fair value through other comprehensive income for the nine months ended September 30, 2025, based on the percentage of ownership of the associates, and the related other equity - unrealized gain was transferred to retained earnings.

As a result of the change in paid-in capital due to the exercise of employee stock options issued by the AmCad BioMed Corporation for the nine months ended September 30, 2024, the Group's shareholding in AmCad BioMed Corporation was reduced to 6.52%, which resulted in a change in the net value of the Group's investment in the Company's net assets, and the capital surplus should be adjusted for a decrease of \$1 thousand.

On July 24, 2024, AmCad BioMed Corporation set the base date for its capital increase and conducted a cash capital increase at a subscription price of NT\$23 per share, and the Group subscribed to 521 thousand shares, with a subscription amount of NT\$11,988 thousand. As the Group did not subscribe to the newly issued shares in proportion to its existing shareholding, its equity interest in AmCad BioMed Corporation was diluted, resulting in a decrease in the Group's shareholding ratio to 6.31% following the capital increase.

Share of the other comprehensive income (loss) of associates accounted for using the equity method is recognized based on the financial statements of each associate reviewed by accountants for the same period.

The information on the Group's associates is summarized as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
The Group's share of:				
Loss from continuing operations	\$ (3,653)	\$ (3,769)	\$ (12,519)	\$ (14,233)
Other comprehensive income (loss)	<u>1,010</u>	<u>(2,051)</u>	<u>(2,783)</u>	<u>9,660</u>
Total comprehensive loss for the period	<u>\$ (2,643)</u>	<u>\$ (5,820)</u>	<u>\$ (15,302)</u>	<u>\$ (4,573)</u>

Information on the level 1 fair value of related companies with open market quotations is as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
PhytoHealth Corporation	<u>\$ 543,897</u>	<u>\$ 590,196</u>	<u>\$ 639,379</u>
AmCad BioMed Corporation	<u>\$ 61,123</u>	<u>\$ 89,288</u>	<u>\$ 90,686</u>

14. PROPERTY, PLANT AND EQUIPMENT

	Land	Buildings	Machinery and Equipment	Income-generat ing Equipment	Other Equipment	Construction in Progress	Total
<u>Cost</u>							
Balance on January 1, 2025	\$ 293,932	\$ 1,076,495	\$ 136,997	\$ 19,233	\$ 1,708	\$ 1,348	\$ 1,529,713
Additions	-	-	-	225	-	10,547	10,772
Reclassification (Note)	-	11,589	1,870	873	150	(11,895)	2,587
Effects of foreign currency exchange differences	-	(5,407)	-	(4)	-	-	(5,411)
Balance on September 30, 2025	<u>\$ 293,932</u>	<u>\$ 1,082,677</u>	<u>\$ 138,867</u>	<u>\$ 20,327</u>	<u>\$ 1,858</u>	<u>\$ -</u>	<u>\$ 1,537,661</u>

(Continued)

	Land	Buildings	Machinery and Equipment	Income-generating Equipment	Other Equipment	Construction in Progress	Total
<u>Accumulated depreciation and impairment</u>							
Balance on January 1, 2025	\$ -	\$ (231,138)	\$ (26,107)	\$ (2,189)	\$ (311)	\$ -	\$ (259,745)
Depreciation expenses	-	(26,494)	(8,696)	(2,045)	(276)	-	(37,511)
Effects of foreign currency exchange differences	-	2,883	-	4	-	-	2,887
Balance on September 30, 2025	<u>\$ -</u>	<u>\$ (254,749)</u>	<u>\$ (34,803)</u>	<u>\$ (4,230)</u>	<u>\$ (587)</u>	<u>\$ -</u>	<u>\$ (294,369)</u>
Carrying amount on December 31, 2024 and January 1, 2025	<u>\$ 293,932</u>	<u>\$ 845,357</u>	<u>\$ 110,890</u>	<u>\$ 17,044</u>	<u>\$ 1,397</u>	<u>\$ 1,348</u>	<u>\$ 1,269,968</u>
Carrying amount on September 30, 2025	<u>\$ 293,932</u>	<u>\$ 827,928</u>	<u>\$ 104,064</u>	<u>\$ 16,097</u>	<u>\$ 1,271</u>	<u>\$ -</u>	<u>\$ 1,243,292</u>
<u>Cost</u>							
Balance on January 1, 2024	\$ 293,932	\$ 389,928	\$ 51,767	\$ 2,515	\$ 2,181	\$ 472,125	\$ 1,212,448
Additions	-	44,643	4,042	1,384	1,708	174,370	226,147
Reclassification (Note)	-	601,353	86,621	14,402	-	(641,454)	60,922
Effects of foreign currency exchange differences	-	5,547	-	5	-	-	5,552
Balance on September 30, 2024	<u>\$ 293,932</u>	<u>\$ 1,041,471</u>	<u>\$ 142,430</u>	<u>\$ 18,306</u>	<u>\$ 3,889</u>	<u>\$ 5,041</u>	<u>\$ 1,505,069</u>
<u>Accumulated depreciation and impairment</u>							
Balance on January 1, 2024	\$ -	\$ (213,815)	\$ (38,498)	\$ (1,776)	\$ (2,156)	\$ -	\$ (256,245)
Depreciation expenses	-	(14,024)	(3,946)	(622)	(250)	-	(18,842)
Effects of foreign currency exchange differences	-	(2,748)	-	(4)	-	-	(2,752)
Balance on September 30, 2024	<u>\$ -</u>	<u>\$ (230,587)</u>	<u>\$ (42,444)</u>	<u>\$ (2,402)</u>	<u>\$ (2,406)</u>	<u>\$ -</u>	<u>\$ (277,839)</u>
Carrying amount on September 30, 2024	<u>\$ 293,932</u>	<u>\$ 810,884</u>	<u>\$ 99,986</u>	<u>\$ 15,904</u>	<u>\$ 1,483</u>	<u>\$ 5,041</u>	<u>\$ 1,227,230</u>

(Concluded)

Note: The reclassification is transferred from the prepayments for equipment.

There was no indication that property, plant and equipment was impaired, so the Group did not perform an impairment test for the nine months ended September 30, 2025 and 2024.

Property, plant and equipment of the Group are depreciated on a straight-line basis over their estimated useful lives as follows:

Buildings	
Main building	34-61 years
Mechanical and electrical engineering	5-20 years
Decoration engineering	5-15 years
Machinery equipment	3-15 years
Income-generating equipment	3-10 years
Other equipment	5 years

The property and plant pledged as collateral for bank borrowings are set out in Note 30.

15. LEASE ARRANGEMENTS

a. Right-of-use assets

	September 30, 2025	December 31, 2024	September 30, 2024	
<u>Carrying amount</u>				
Transportation equipment	<u>\$ 7,784</u>	<u>\$ 4,255</u>	<u>\$ 4,699</u>	
	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Additions to right-of-use assets			<u>\$ 5,708</u>	<u>\$ 4,054</u>
Depreciation charge for right-of-use assets				
Buildings	\$ -	\$ -	\$ -	\$ 2,698
Transportation equipment	<u>540</u>	<u>696</u>	<u>1,429</u>	<u>1,245</u>
	<u>\$ 540</u>	<u>\$ 696</u>	<u>\$ 1,429</u>	<u>\$ 3,943</u>

Except for the aforementioned additions and recognized depreciation, the Group did not have significant sublease or impairment of right-of-use assets for the nine months ended September 30, 2025 and 2024.

b. Lease liabilities

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Carrying amounts</u>			
Current	<u>\$ 2,453</u>	<u>\$ 1,818</u>	<u>\$ 1,813</u>
Non-current	<u>\$ 5,475</u>	<u>\$ 2,504</u>	<u>\$ 2,949</u>

Range of discount rate for lease liabilities was as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Buildings	-	1.079%	1.079%
Transportation equipment	1.211%	1.079%-1.211%	1.079%-1.211%

c. Material leasing activities and terms

The Group leases transportation equipment for general operating activities for the period of 3 to 5 years.

At the end of the lease term, the Group does not have bargain purchase options to acquire the above lease properties.

d. Other lease information

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Expenses relating to short-term leases	\$ <u>726</u>	\$ <u>501</u>	\$ <u>1,887</u>	\$ <u>1,725</u>
Expenses relating to low-value asset leases	\$ <u>87</u>	\$ <u>87</u>	\$ <u>261</u>	\$ <u>254</u>
Total cash outflow for leases			\$ <u>(3,537)</u>	\$ <u>(5,960)</u>

The Group elected to apply the exemption from recognition to certain leases of office equipment that qualify as short-term leases of buildings and construction and that qualify as low-value leases of assets, and not to recognize the related right-of-use assets and lease liabilities for these leases.

16. OTHER ASSETS

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Current</u>			
Temporary payments	\$ <u>1,245</u>	\$ <u>380</u>	\$ <u>1,019</u>
<u>Non-current</u>			
Prepayments for equipment	\$ <u>385</u>	\$ <u>-</u>	\$ <u>-</u>

17. BORROWINGS

a. Short-term borrowings

	September 30, 2025	December 31, 2024	September 30, 2024
Unsecured borrowings			
Line of credit borrowings	\$ <u>-</u>	\$ <u>35,000</u>	\$ <u>35,000</u>

The revolving bank loan was drawn down in March 2024 and was scheduled to mature in March 2025, with an effective interest rate of 0.5%.

b. Long-term borrowings

	September 30, 2025	December 31, 2024	September 30, 2024
Secured borrowings (Note 30)			
Bank loans	\$ <u>634,464</u>	\$ <u>634,464</u>	\$ <u>558,938</u>

Bank loan's floating rates of the bank loans, which the Group used to build a factory, are calculated monthly on the balance of the principal, with interest paid monthly for the first 66 months and the principal repayable in equal monthly installments from the 67th month (February 2028) onward, at an effective interest rate of 0.68% to 1.91% per annum, and the loan period is eight years. The Group used the loan to build a factory.

18. NOTES PAYABLE AND ACCOUNTS PAYABLE

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Notes payable</u>			
Operating	\$ <u>17</u>	\$ <u>10</u>	\$ <u>84</u>
<u>Accounts payable</u>			
Operating	\$ 46,040	\$ 76,670	\$ 53,697
Related parties (Note 29)	<u>30,887</u>	<u>19,728</u>	<u>29,407</u>
	<u>\$ 76,927</u>	<u>\$ 96,398</u>	<u>\$ 83,104</u>

Accounts Payable

The Group has a financial risk management policy to ensure that all accounts payable are repaid within the prearranged credit period, which ranges from one to six months.

19. OTHER PAYABLES

	September 30, 2025	December 31, 2024	September 30, 2024
Payables for promotion fee	\$ 98,010	\$ 83,419	\$ 87,209
Payables for advertising fee	75,407	69,153	67,166
Payables for salaries and bonuses	50,800	55,463	44,044
Construction payable	-	-	54,588
Equipment payable	-	1,915	-
Others	<u>35,252</u>	<u>40,025</u>	<u>31,560</u>
	<u>\$ 259,469</u>	<u>\$ 249,975</u>	<u>\$ 284,567</u>

20. RETIREMENT BENEFIT PLANS

The pension expenses of the defined benefit plan were calculated based on the actuarially determined pension cost rate on December 31, 2024 and 2023. An analysis by function of the pension expense was as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Operating expenses	\$ <u>(245)</u>	\$ <u>(92)</u>	\$ <u>(736)</u>	\$ <u>(275)</u>

21. EQUITY

a. Share capital

Ordinary shares

	September 30, 2025	December 31, 2024	September 30, 2024
Shares authorized (in thousands of shares)	<u>300,000</u>	<u>300,000</u>	<u>300,000</u>
Shares authorized	<u>\$ 3,000,000</u>	<u>\$ 3,000,000</u>	<u>\$ 3,000,000</u>
Shares issued and fully paid (in thousands of shares)	<u>132,915</u>	<u>132,915</u>	<u>132,915</u>
Shares issued and fully paid	<u>\$ 1,329,152</u>	<u>\$ 1,329,152</u>	<u>\$ 1,329,152</u>

b. Capital surplus

	September 30, 2025	December 31, 2024	September 30, 2024
<u>May be used to offset a deficit, distributed as cash dividends, or transferred to share capital (Note 1)</u>			
Issuance of ordinary shares	\$ 161,940	\$ 161,940	\$ 161,940
<u>May only be used to offset a deficit</u>			
Share of changes in capital surplus of associates	29,193	29,142	29,410
Dividends unclaimed by shareholders (Note 2)	<u>1,075</u>	<u>1,075</u>	<u>1,075</u>
	<u>\$ 192,208</u>	<u>\$ 192,157</u>	<u>\$ 192,425</u>

Note 1: Such capital surplus may be used to offset a deficit; in addition, when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's capital surplus and once a year).

Note 2: According to the letter Jingshangzi No. 10602420200 issued by the Ministry of Economic Affairs on September 21, 2017, unclaimed dividends should be recognized as capital reserves.

A reconciliation of the carrying amount for the nine months ended September 30, 2025 and 2024 for each class of capital surplus was as follows:

	Issuance of Ordinary Shares	Changes in Capital Surplus from Investment in Associates Accounted for Using the Equity Method	Dividends Unclaimed by Shareholders	Total
Balance on January 1, 2025	\$ 161,940	\$ 29,142	\$ 1,075	\$ 192,157
Changes in capital surplus from investments in associates accounted for using the equity method	_____ -	_____ 51	_____ -	_____ 51
Balance on September 30, 2025	<u>\$ 161,940</u>	<u>\$ 29,193</u>	<u>\$ 1,075</u>	<u>\$ 192,208</u>
Balance on January 1, 2024	\$ 161,940	\$ 26,305	\$ 1,075	\$ 189,320
Changes in capital surplus from investments in associates accounted for using the equity method	_____ -	_____ 3,105	_____ -	_____ 3,105
Balance on September 30, 2024	<u>\$ 161,940</u>	<u>\$ 29,410</u>	<u>\$ 1,075</u>	<u>\$ 192,425</u>

c. Retained earnings and dividends policy

Under the dividends policy as set forth in the Articles, where the Company made a profit in a fiscal year, the profit shall be first utilized for paying taxes, offsetting losses of previous years, setting aside as legal reserve 10% of the remaining profit, setting aside or reversing a special reserve in accordance with the laws and regulations, and then any remaining profit together with any undistributed retained earnings at least used 10% by the Company's board of directors as the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders. For the policies on the distribution of compensation of employees and remuneration of directors after the amendment, refer to compensation of employees and remuneration of directors in Note 23 (g).

Appropriation of earnings to the legal reserve shall be made until the legal reserve equals the Company's paid-in capital. The legal reserve may be used to offset deficits. If the Company has no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

When the Company makes a provision for the special surplus reserve for the net reduction of other benefits accumulated in the previous period, it only makes a provision for the undistributed surplus of the previous period.

The appropriations of earnings for 2024 and 2023 that had been resolved by the shareholders in their meeting on June 5, 2025 and May 29, 2024, respectively, were as follows:

	Appropriation of Earnings	
	For the Year Ended December 31	
	2024	2023
Legal reserve	\$ 19,222	\$ 16,875
Reversal of special reserve	\$ (27,459)	\$ (16,341)
Cash dividends	\$ 159,497	\$ 152,853
Cash dividends per share (NT\$)	\$ 1.20	\$ 1.15

d. Special reserve

The cumulative translation adjustment transferred to retained earnings was \$8,874 thousand when the Company initially adopted IFRS Accounting Standards. The increase in retained earnings from the initial adoption of IFRS Accounting Standards was not enough to provide for the increase in retained earnings, so only a special reserve of \$1,875 thousand was provided for the increase in retained earnings from the conversion to IFRS Accounting Standards.

e. Other equity items

	September 30, 2025	December 31, 2024	September 30, 2024
Exchange differences on translation of financial statements of foreign operations attributable to the Company	<u>\$ (19,215)</u>	<u>\$ (13,199)</u>	<u>\$ (11,762)</u>
Unrealized valuation loss on financial assets at FVTOCI attributable to the Company	(86,585)	(79,560)	(70,571)
Share from associates accounted for using the equity method	<u>20,253</u>	<u>30,397</u>	<u>32,117</u>
	<u>(66,332)</u>	<u>(49,163)</u>	<u>(38,454)</u>
	<u>\$ (85,547)</u>	<u>\$ (62,362)</u>	<u>\$ (50,216)</u>

1) Exchange differences on translation of financial statements of foreign operations

Translation differences arising from the translation of the net assets of foreign operations from their functional currency into the Company's presentation currency (i.e., New Taiwan dollars) are recognized directly in other comprehensive income as translation differences in the financial statements of foreign operations. The cumulative translation differences on the financial statements of foreign operations are transferred to profit or loss upon disposal of the foreign operations.

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ (13,199)	\$ (18,070)
Recognized for the period		
Exchange differences on translation of financial statements of foreign operations	<u>(6,016)</u>	<u>6,308</u>
Other comprehensive income (loss) recognized for the period	<u>(6,016)</u>	<u>6,308</u>
Balance on September 30	<u>\$ (19,215)</u>	<u>\$ (11,762)</u>

2) Unrealized valuation gain (loss) on financial assets at FVTOCI

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ (49,163)	\$ (71,751)
Recognized for the period		
Unrealized gain equity instruments	343	23,637
Share from associates accounted for using the equity method	<u>(2,783)</u>	<u>9,660</u>
Other comprehensive income (loss)	<u>(2,440)</u>	<u>33,297</u>
Cumulative unrealized loss of equity instruments transferred to retained earnings due to disposal	<u>(14,729)</u>	<u>-</u>
Balance on September 30	<u>\$ (66,332)</u>	<u>\$ (38,454)</u>

Please refer to Note 28 (b) for the reconciliation of the Level 3 fair value measurements of financial assets at fair value through other comprehensive income.

22. REVENUE

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Revenue from contracts with customers				
Revenue from the sale of goods				
Consumer business unit	\$ 257,319	\$ 246,320	\$ 819,908	\$ 780,571
Pharmaceutical business unit	<u>114,932</u>	<u>105,484</u>	<u>349,332</u>	<u>329,208</u>
	<u>\$ 372,251</u>	<u>\$ 351,804</u>	<u>\$ 1,169,240</u>	<u>\$ 1,109,779</u>

Revenue from Sale of Goods

The Group's sales come from various channels, such as e-commerce, medical institutions, wholesalers and retailers, and discounts are granted to different sales targets on different terms. Revenue is measured at the fair value of the consideration received or receivable, less estimated customer returns, discounts and other similar discounts.

Contract Balances

	September 30, 2025	December 31, 2024	September 30, 2024	January 1, 2024
Notes receivable (Note 8)	<u>\$ 12,533</u>	<u>\$ 11,145</u>	<u>\$ 11,738</u>	<u>\$ 22,522</u>
Accounts receivable (Note 8)	<u>\$ 276,640</u>	<u>\$ 239,286</u>	<u>\$ 248,010</u>	<u>\$ 226,268</u>

23. NET PROFIT

a. Interest income

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Bank deposits	\$ <u>1,742</u>	\$ <u>1,855</u>	\$ <u>5,936</u>	\$ <u>6,187</u>

b. Other income

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Rental income	\$ 2,665	\$ 2,822	\$ 8,174	\$ 8,440
Dividend income	2,059	2,566	8,880	7,682
Other income	<u>419</u>	<u>245</u>	<u>1,150</u>	<u>2,321</u>
	\$ <u>5,143</u>	\$ <u>5,633</u>	\$ <u>18,204</u>	\$ <u>18,443</u>

c. Other gains and losses

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Fair value changes of financial assets				
Financial assets mandatorily classified as at FVTPL	\$ 102	\$ 26	\$ 281	\$ 60
Net foreign exchange gains	260	131	978	529
Gain on lease modification	<u>6</u>	<u>-</u>	<u>6</u>	<u>-</u>
	\$ <u>368</u>	\$ <u>157</u>	\$ <u>1,265</u>	\$ <u>589</u>

d. Interest expense

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Interest on bank loans	\$ 2,115	1,729	\$ 6,029	\$ 4,564
Interest on lease liabilities	19	24	42	41
Less: Capitalized interest	<u>-</u>	<u>(558)</u>	<u>-</u>	<u>(3,334)</u>
	\$ <u>2,134</u>	\$ <u>1,195</u>	\$ <u>6,071</u>	\$ <u>1,271</u>

Information about capitalized interest was as follows:

	For the Nine Months Ended September 30	
	2025	2024
Capitalized interest amount	\$ <u>-</u>	\$ <u>3,334</u>
Capitalization rate	-	1.08%-1.21%

e. Depreciation and amortization expense

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Analysis of depreciation by function				
Operating costs	\$ 4,502	\$ 3,008	\$ 13,378	\$ 9,848
Operating expenses	<u>8,463</u>	<u>6,923</u>	<u>25,562</u>	<u>12,937</u>
	<u>\$ 12,965</u>	<u>\$ 9,931</u>	<u>\$ 38,940</u>	<u>\$ 22,785</u>
Analysis of amortization by function				
Operating costs	\$ 496	\$ 280	\$ 1,370	\$ 724
Operating expenses	<u>185</u>	<u>204</u>	<u>538</u>	<u>655</u>
	<u>\$ 681</u>	<u>\$ 484</u>	<u>\$ 1,908</u>	<u>\$ 1,379</u>

f. Employee benefits expense

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Post-employment benefits				
Defined contribution plan	\$ 1,994	\$ 1,977	\$ 6,103	\$ 5,901
Defined benefit plans (Note 20)	(245)	(92)	(736)	(275)
Other employee benefits				
Salaries and bonuses	45,679	45,175	142,889	137,801
Labor and health insurance	4,045	3,744	12,491	11,813
Others	<u>1,957</u>	<u>1,931</u>	<u>5,966</u>	<u>5,272</u>
Total employee benefits expense	<u>\$ 53,430</u>	<u>\$ 52,735</u>	<u>\$ 166,713</u>	<u>\$ 160,512</u>
Analysis of employee benefits expense by function				
Operating expenses	\$ 41,842	\$ 41,513	\$ 130,712	\$ 124,771
Operating costs	<u>11,588</u>	<u>11,222</u>	<u>36,001</u>	<u>35,741</u>
	<u>\$ 53,430</u>	<u>\$ 52,735</u>	<u>\$ 166,713</u>	<u>\$ 160,512</u>

g. Compensation of employees and remuneration of directors

According to the Company's Articles, the Company accrues compensation of employees and remuneration of directors at rates of 3%-6% and no higher than 4%, respectively, of net profit before income tax, compensation of employees, and remuneration of directors. In accordance with the amendments to the Securities and Exchange Act in August 2024, the shareholders of the Company resolved the amendments to the Company's Articles at their 2025 regular meeting. The amendments explicitly stipulate the allocation of no less than 20% of the compensation of employees in a given year as compensation distributions for non-executive employees. The compensation of employees (including non-executive employees) and the remuneration of directors for the three months ended September 30, 2025 and 2024 and for the nine months ended September 30, 2025 and 2024 are as follows:

Accrual rate

	For the Nine Months Ended September 30	
	2025	2024
Compensation of employees	3%	3%
Remuneration of directors	2%	2%

Amount

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
	Cash	Cash	Cash	Cash
Compensation of employees	<u>\$ 1,632</u>	<u>\$ 1,576</u>	<u>\$ 5,874</u>	<u>\$ 5,696</u>
Remuneration of directors	<u>\$ 1,088</u>	<u>\$ 1,050</u>	<u>\$ 3,916</u>	<u>\$ 3,797</u>

If there is a change in the amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The appropriations of employees' compensation and remuneration of directors for 2024 and 2023 that were resolved by the board of directors on February 27, 2025 and February 27, 2024, respectively, are as shown below:

	2024	2023
	Cash	Cash
Compensation of employees	\$ 6,892	\$ 6,639
Remuneration of directors	4,595	4,426

There is no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the consolidated financial statements for the years ended December 31, 2024 and 2023.

Information on compensation of employees and remuneration of directors resolved by the Company's board of directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

h. Gains or losses on foreign currency exchange

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Foreign exchange gains	\$ 342	\$ 217	\$ 1,686	\$ 943
Foreign exchange losses	<u>(82)</u>	<u>(86)</u>	<u>(708)</u>	<u>(414)</u>
Net gains	<u>\$ 260</u>	<u>\$ 131</u>	<u>\$ 978</u>	<u>\$ 529</u>

24. INCOME TAXES RELATING

a. Income tax recognized in profit or loss

Major components of income tax expense (benefit) are as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Current tax				
In respect of the current period	\$ 12,134	\$ 11,122	\$ 44,132	\$ 44,764
Income tax on unappropriated earnings	-	-	2,048	-
Adjustments for prior year	-	-	(2,019)	(1,127)
Deferred tax				
In respect of the current period	<u>(1,171)</u>	<u>(629)</u>	<u>(6,410)</u>	<u>(7,531)</u>
Income tax expense recognized in profit or loss	<u>\$ 10,963</u>	<u>\$ 10,493</u>	<u>\$ 37,751</u>	<u>\$ 36,106</u>

b. Income tax assessment

The income tax returns through 2023 have been assessed by the tax authorities, there is no difference between the amount of approved and declared tax.

25. EARNINGS PER SHARE

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share were as follows:

Net Profit for the Period

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Net profit attributable to owners of the Company	<u>\$ 40,118</u>	<u>\$ 39,431</u>	<u>\$ 145,655</u>	<u>\$ 144,263</u>

Shares

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Weighted average number of ordinary shares used in the computation of basic earnings per share	132,915	132,915	132,915	132,915
Effect of potentially dilutive ordinary shares				
Compensation of employees	<u>45</u>	<u>237</u>	<u>330</u>	<u>294</u>
Weighted average number of ordinary shares used in the computation of diluted earnings per share	<u>132,960</u>	<u>133,152</u>	<u>133,245</u>	<u>133,209</u>

The Group may settle the compensation of employees in cash or shares; therefore, the Group assumes that the entire amount of the compensation will be settled in shares, and the resulting potential shares will be included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

26. CASH FLOW INFORMATION

a. Non-cash transactions

In addition to those disclosed in other notes, the Group entered into the following non-cash investing activities, which were not reflected in the consolidated statements of cash flows for the nine months ended September 30, 2025:

As of December 31, 2024, the unpaid amount for acquiring property, plant and equipment was \$1,915 thousand, which was recognized in other payables.

b. Changes in liabilities arising from financing activities

For the nine months ended September 30, 2025

	Opening Balance	Cash Flows	Non-cash Changes				Closing Balance
			New Lease	Lease Modification	Amortization of Interest	Others	
Short-term borrowings	\$ 35,000	\$ (35,000)	\$ -	\$ -	\$ -	\$ -	\$ -
Long-term borrowings	634,464	-	-	-	-	-	634,464
Lease liabilities	4,322	(1,346)	5,708	(756)	42	(42)	7,928
Guarantee deposits	<u>1,945</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,945</u>
	<u>\$ 675,731</u>	<u>\$ (36,346)</u>	<u>\$ 5,708</u>	<u>\$ (756)</u>	<u>\$ 42</u>	<u>\$ (42)</u>	<u>\$ 644,337</u>

For the nine months ended September 30, 2024

	Opening Balance	Cash Flows	Non-cash Changes			Closing Balance
			New Leases	Amortization of Interest	Others	
Short-term borrowings	\$ -	\$ 35,000	\$ -	\$ -	\$ -	\$ 35,000
Long-term borrowings	437,893	121,045	-	-	-	558,938
Lease liabilities	4,648	(3,940)	4,054	41	(41)	4,762
Guarantee deposits	<u>1,945</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,945</u>
	<u>\$ 444,486</u>	<u>\$ 152,105</u>	<u>\$ 4,054</u>	<u>\$ 41</u>	<u>\$ (41)</u>	<u>\$ 600,645</u>

27. CAPITAL RISK MANAGEMENT

The objective of the Group's capital management is to ensure that the companies in the Group can continue to operate, and maximize shareholder returns by optimizing the balance of debt and equity.

The capital structure of the Group consists of net debt (borrowings offset by cash and cash equivalents) and equity attributable to owners of the Company (comprising issued capital, reserves, retained earnings and other equity).

28. FINANCIAL INSTRUMENTS

a. Fair value of financial instruments not measured at fair value

Among the financial assets and financial liabilities not measured at fair value, there is no material difference between the carrying amount and the fair value.

b. Fair value of financial instruments measured at fair value on a recurring basis

1) Fair value hierarchy

September 30, 2025

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTOCI</u>				
Investments in equity instruments at FVTOCI				
Domestic listed shares	\$ 24,206	\$ -	\$ -	\$ 24,206
Domestic unlisted shares	-	-	81,791	81,791
Foreign unlisted shares	<u>-</u>	<u>-</u>	<u>6,284</u>	<u>6,284</u>
	<u>\$ 24,206</u>	<u>\$ -</u>	<u>\$ 88,075</u>	<u>\$ 112,281</u>

December 31, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTPL</u>				
Mutual funds	\$ <u>12,000</u>	\$ <u>-</u>	\$ <u>-</u>	\$ <u>12,000</u>
<u>Financial assets at FVTOCI</u>				
Investments in equity instruments at FVTOCI				
Domestic listed shares	\$ 49,360	\$ -	\$ -	\$ 49,360
Domestic unlisted shares	-	-	79,314	79,314
Foreign unlisted shares	-	-	<u>6,932</u>	<u>6,932</u>
	\$ <u>49,360</u>	\$ <u>-</u>	\$ <u>86,246</u>	\$ <u>135,606</u>

September 30, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTOCI</u>				
Investments in equity instruments at FVTOCI				
Domestic listed shares	\$ 62,031	\$ -	\$ -	\$ 62,031
Domestic unlisted shares	-	-	81,889	81,889
Foreign unlisted shares	-	-	<u>6,822</u>	<u>6,822</u>
	\$ <u>62,031</u>	\$ <u>-</u>	\$ <u>88,711</u>	\$ <u>150,742</u>

There was no transfer between Level 1 and Level 2 for the nine months ended September 30, 2025 and 2024.

2) Reconciliation of Level 3 fair value measurements of financial instruments

Financial assets at FVTOCI - equity instruments

	For the Nine Months Ended September 30	
	2025	2024
Balance on January 1	\$ 86,246	\$ 84,581
Recognized in other comprehensive income (included in unrealized valuation gain/(loss) on financial assets at FVTOCI)	<u>1,829</u>	<u>4,130</u>
Balance on September 30	\$ <u>88,075</u>	\$ <u>88,711</u>

3) Level 3 valuation techniques and inputs for measuring fair value

Investments in domestic and foreign unlisted equity are calculated by the market approach or asset approach, and the fair value of the investment target is calculated.

In the market approach, the fair value of the investment target is determined based on the transaction price of the stock of companies engaged in similar businesses in the active market, the value multiplier implied by the price, and the discount for lack of marketability.

In the asset approach, the market value of individual assets and liabilities covered by the investment target is used to reflect the value of the business or activities.

c. Categories of financial instruments

	September 30, 2025	December 31, 2024	September 30, 2024
<u>Financial assets</u>			
Financial assets recognized at FVTPL	\$ -	\$ 12,000	\$
Financial assets at amortized cost (Note 1)	817,250	850,970	807,242
Financial assets recognized at FVTOCI			
Equity instruments	112,281	135,606	150,742
<u>Financial liabilities</u>			
Financial liabilities at amortized cost (Note 2)	922,022	962,329	919,594

Note 1: The balances include financial assets at amortized cost, which comprise cash and cash equivalents, notes receivable, accounts receivable, other receivables, other financial assets and refundable deposits.

Note 2: The balances include financial liabilities at amortized cost, which comprise notes payable, accounts payable, other payables (excluding salaries and bonuses payable), long-term borrowings, short-term borrowings and guarantee deposits.

d. Financial risk management objectives and policies

The Group's major financial instruments include equity investments, accounts receivable, other financial assets, accounts payable, borrowings and lease liabilities. The Group's corporate treasury function provides services to the business, coordinates access to domestic and international financial markets, and monitors and manages the financial risks relating to the operations of the Group through internal risk reports that analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risk), credit risk and liquidity.

1) Market risk

The Group's activities exposed it primarily to the financial risks of changes in foreign currency exchange rates, interest rates and other prices.

There had been no change to the Group's exposure to market risks or the manner in which these risks were managed and measured.

a) Foreign currency risk

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are set out in Note 33.

Sensitivity analysis

The Group is mainly exposed to the USD, JPY and EUR.

The following table details the Group's sensitivity to a 5% increase or decrease in the New Taiwan dollar (the functional currency) against the relevant foreign currencies. The sensitivity rate used when reporting foreign currency risk internally to key management personnel and representing management's assessment of the reasonably possible change in foreign exchange rates is 5%. For a 5% weakening of the New Taiwan dollar against the relevant currency, there would be an equal and opposite impact on pre-tax profit and other equity, and the balances below would be negative (positive).

	<u>USD Impact</u>		<u>JPY Impact</u>		<u>EUR Impact</u>	
	<u>For the Nine Months Ended</u>		<u>For the Nine Months Ended</u>		<u>For the Nine Months Ended</u>	
	<u>September 30</u>		<u>September 30</u>		<u>September 30</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Profit or loss	\$ (19)	\$ (78)	\$ 35	\$ -	\$ (30)	\$ 38

The above effects of profit and loss were mainly derived from the Group's foreign currency deposits and accounts payable valued in the USD, JPY and EUR which were still circulating at the balance sheet date.

The Group's sensitivity to USD decreased, JPY increased and EUR decreased respectively during the current period mainly due to a reduction in USD-denominated assets, an expansion of JPY-denominated assets and a reduction in EUR-denominated assets.

b) Interest rate risk

The carrying amounts of the Group's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	<u>September 30,</u>	<u>December 31,</u>	<u>September 30,</u>
	<u>2025</u>	<u>2024</u>	<u>2024</u>
Fair value interest rate risk			
Financial assets	\$ 38,552	\$ 128,000	\$ 203,675
Financial liabilities	7,928	4,322	4,762
Cash flow interest rate risk			
Financial assets	481,506	465,358	336,115
Financial liabilities	634,464	669,464	593,938

Sensitivity analysis

The sensitivity analysis below was determined based on the Group's exposure to interest rates for both derivative and non-derivative instruments at the end of the year. For floating rate liabilities, the analysis was prepared assuming the amount of each liability outstanding at the end of the year was outstanding for the whole year. A 12.5 basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

If interest rates had been 12.5 basis points higher/lower and all other variables were held constant, the Group's pre-tax profit for the nine months ended September 30, 2025 and 2024 would have increased/decreased by \$(143) thousand and \$(242) thousand, respectively, which was mainly a result of bank deposits and long-term borrowings.

The Group's sensitivity to interest rates decreased during the current year mainly due to the decrease in net cash flow-generating financial liabilities during the current year.

c) Other price risk

The Group was exposed to equity price risk through its investments in listed or unlisted equity securities.

Sensitivity analysis

The sensitivity analysis below was determined based on the exposure to equity price risks at the end of the period.

If equity prices had been 5% higher/lower, pre-tax other comprehensive income for the nine months ended September 30, 2025 and 2024 would have increased/decreased by \$5,614 thousand and \$7,537 thousand, respectively, as a result of the changes in fair value of financial assets at FVTOCI.

The Group's sensitivity to price risk decreased during the current period due to the sale of the equity securities held by the Group.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. As the end of the year, the Group's maximum exposure to credit risk, which would cause a financial loss to the Group due to the failure of counterparties to discharge an obligation and due to financial guarantee provided by the Group, could be equal to the total of the carrying amount of the respective recognized financial assets as stated in the balance sheet.

The Group adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from defaults.

The Group's accounts receivable cover a wide range of customers in different industries and geographical areas; therefore, the Group does not have significant credit risk to any single counterparty or any group of counterparties with similar characteristics.

3) Liquidity risk

The Group manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents deemed adequate to finance the Group's operations and mitigate the effects of fluctuations in cash flows.

The Group's remaining contractual maturities for its non-derivative financial liabilities with agreed upon repayment periods that have been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Group can be required to pay include both interest and principal cash flows. Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

September 30, 2025

	Within 3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>				
Non-interest bearing	\$ 285,613	\$ -	\$ 1,945	\$ -
Lease liabilities	723	1,813	5,983	-
Variable interest rate liabilities	<u>3,031</u>	<u>9,092</u>	<u>664,265</u>	<u>-</u>
	<u>\$ 289,367</u>	<u>\$ 10,905</u>	<u>\$ 672,193</u>	<u>\$ -</u>

December 31, 2024

	Within 3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>				
Non-interest bearing	\$ 290,920	\$ -	\$ 1,945	\$ -
Lease liabilities	500	1,359	2,532	-
Variable interest rate liabilities	<u>36,920</u>	<u>4,581</u>	<u>545,959</u>	<u>127,398</u>
	<u>\$ 328,340</u>	<u>\$ 5,940</u>	<u>\$ 550,436</u>	<u>\$ 127,398</u>

September 30, 2024

	Within 3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>				
Non-interest bearing	\$ 323,711	\$ -	\$ 1,945	\$ -
Lease liabilities	500	1,359	2,985	-
Variable interest rate liabilities	<u>1,692</u>	<u>5,075</u>	<u>85,472</u>	<u>513,457</u>
	<u>\$ 325,903</u>	<u>\$ 6,434</u>	<u>\$ 90,402</u>	<u>\$ 513,457</u>

Financing facilities

	September 30, 2025	December 31, 2024	September 30, 2024
Unsecured bank facilities (reviewed annually)			
Amount used	\$ -	\$ 35,000	\$ 35,000
Amount unused	<u>-</u>	<u>-</u>	<u>-</u>
	<u>\$ -</u>	<u>\$ 35,000</u>	<u>\$ 35,000</u>

(Continued)

	September 30, 2025	December 31, 2024	September 30, 2024
Secured bank facilities			
Amount used	\$ 634,464	\$ 634,464	\$ 558,938
Amount unused	<u> -</u>	<u> 51,536</u>	<u> 127,062</u>
	<u>\$ 634,464</u>	<u>\$ 686,000</u>	<u>\$ 686,000</u>
			(Concluded)

29. TRANSACTIONS WITH RELATED PARTIES

a. Related parties

Related Party Name	Related Party Category
PhytoHealth Corporation	Investments accounted for using the equity method (associate)
AmCad BioMed Corporation	Investments accounted for using the equity method (associate)
Broadsound Corporation	Investments accounted for using the equity method (associate)
Lu Te Na a Limited	Investments accounted for using the equity method (associate)
Taiwan Incubator SME Development Corp.	The same chairman as the Company (other related parties)

b. Besides information disclosed elsewhere in the other notes, details of transactions between the Group and other related parties are disclosed as follows:

1) Operating transactions

Line Item	Related Party Category	For the Three Months Ended September 30		For the Nine Months Ended September 30	
		2025	2024	2025	2024
Operating revenue	Associates	<u>\$ 2,211</u>	<u>\$ 1,311</u>	<u>\$ 3,319</u>	<u>\$ 4,943</u>
	Other related parties	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 3</u>	<u>\$ 5</u>

The Group had signed a contract with PhytoHealth Corporation to sell its products. The Group is responsible for sell its promotion business of medicine and health care products. According to the terms of the contract, service will be charged monthly.

Line Item	Related Party Category/Name	For the Three Months Ended September 30		For the Nine Months Ended September 30	
		2025	2024	2025	2024
Operating costs	Purchases of goods PhytoHealth Corporation	<u>\$ 29,412</u>	<u>\$ 27,991</u>	<u>\$ 75,775</u>	<u>\$ 80,121</u>
	Other operation costs associates	<u>\$ 9</u>	<u>\$ 16</u>	<u>\$ 26</u>	<u>\$ 32</u>

The Group had signed a contract with PhytoHealth Corporation to sell its products “PG2® Lyo. Injection”, and other drugs in Taiwan. The contract term is set to start in January 2014 to December 2016. If a party is not notified the contract would not be renewed in writing by the expiration date, and the contract would automatically be renewed for one more year.

The Group had signed a contract with AmCad BioMed Corporation to sell its products “AmCAD-Ute” in Taiwan. The contract term is set to start on April 24, 2015 and end on March 31, 2018. If a party is not notified the contract would not be renewed in writing by the expiration date, and the contract would automatically be renewed for one more year. The Group issued a guarantee note for \$10,000 thousand as collateral of payment.

The purchases and sales prices and payment terms to related parties were not significantly different from those of sales to third parties.

2) Receivables from related parties

Line Item	Related Party Category/Name	September 30, 2025	December 31, 2024	September 30, 2024
Accounts receivable	Associates	<u>\$ 35</u>	<u>\$ 24</u>	<u>\$ 77</u>
Other receivables	PhytoHealth Corporation	\$ 927	\$ 884	\$ 1,304
	AmCad BioMed Corporation	<u>33</u>	<u>36</u>	<u>34</u>
		<u>\$ 960</u>	<u>\$ 920</u>	<u>\$ 1,338</u>

The outstanding accounts receivable from related parties are unsecured. For the nine months ended September 30, 2025 and 2024, no impairment losses were recognized for accounts receivable from related parties.

Other receivables represent payments made on behalf of the Group.

3) Payables to related parties

Line Item	Related Party Category/Name	September 30, 2025	December 31, 2024	September 30, 2024
Accounts payable	PhytoHealth Corporation	\$ 30,882	\$ 19,717	\$ 29,390
	Associates	<u>5</u>	<u>11</u>	<u>17</u>
		<u>\$ 30,887</u>	<u>\$ 19,728</u>	<u>\$ 29,407</u>
Other payables	PhytoHealth Corporation	<u>\$ 2,429</u>	<u>\$ -</u>	<u>\$ -</u>

4) Refundable deposits

Related Party Category/Name	September 30, 2025	December 31, 2024	September 30, 2024
PhytoHealth Corporation	\$ 1,448	\$ 1,448	\$ 1,448
AmCad BioMed Corporation	<u>249</u>	<u>249</u>	<u>249</u>
	<u>\$ 1,697</u>	<u>\$ 1,697</u>	<u>\$ 1,697</u>

The refundable deposits are deposits received from PhytoHealth Corporation and AmCad BioMed Corporation for the rental of a plant and warehouse.

5) Lease arrangements

Lease arrangements - the lessor of the Group under an operating lease

The Group leases the part of the plant to AmCad BioMed Corporation and PhytoHealth Corporation under an operating lease. Part of the lease agreement is specified the lease period will be automatically extended for one year if there are no objections for each other three months prior to the expiration each year.

Lease receivables were as follows:

Related Party Category/Name	September 30, 2025	December 31, 2024	September 30, 2024
PhytoHealth Corporation	\$ 551	\$ 551	\$ 551
AmCad BioMed Corporation	<u>85</u>	<u>98</u>	<u>98</u>
	<u>\$ 636</u>	<u>\$ 649</u>	<u>\$ 649</u>

Lease payments to be received in the future were as follows:

Related Party Category/Name	September 30, 2025	December 31, 2024	September 30, 2024
PhytoHealth Corporation	\$ 7,166	\$ 5,591	\$ 7,166
AmCad BioMed Corporation	813	652	932
Lu Te Na Company Limited	<u>-</u>	<u>36</u>	<u>45</u>
	<u>\$ 7,979</u>	<u>\$ 6,279</u>	<u>\$ 8,143</u>

Total lease revenue was as follows:

Related Party Category/Name	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
PhytoHealth Corporation	\$ 1,575	\$ 1,575	\$ 4,725	\$ 4,725
AmCad BioMed Corporation	244	279	755	838
Lu Te Na Company Limited	<u>-</u>	<u>9</u>	<u>3</u>	<u>27</u>
	<u>\$ 1,819</u>	<u>\$ 1,863</u>	<u>\$ 5,483</u>	<u>\$ 5,590</u>

The rental amounts and collection methods are similar to that of general leasing transactions.

c. Remuneration of key management personnel

The remuneration directors and other key management personnel were as follows:

	For the Three Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Short-term employee benefits	\$ 4,413	\$ 13,335	\$ 20,187	\$ 33,883
Post-employment benefits	<u>124</u>	<u>165</u>	<u>368</u>	<u>449</u>
	<u>\$ 4,537</u>	<u>\$ 13,500</u>	<u>\$ 20,555</u>	<u>\$ 34,332</u>

The remuneration of directors and key executives was determined by the remuneration committee based on the performance of individuals and market trends.

30. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets had been pledged as collateral for long-term borrowings:

	September 30, 2025	December 31, 2024	September 30, 2024
Land	\$ 68,149	\$ 74,189	\$ 74,189
Buildings	<u>675,657</u>	<u>741,266</u>	<u>703,960</u>
	<u>\$ 743,806</u>	<u>\$ 815,455</u>	<u>\$ 778,149</u>

31. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED COMMITMENTS

In addition to those disclosed in other notes, significant contingencies and unrecognized commitments of the Group were as follows:

As of September 30, 2025, December 31, 2024 and September 30, 2024, the Group issued and deposited guarantee notes as purchase and performance guarantee, both of which are \$10,000 thousand.

32. SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

None.

33. SIGNIFICANT ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Group's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Group and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

(In Thousands of New Taiwan Dollars and Foreign Currencies)

September 30, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 12	30.45 (USD:NTD)	\$ 381
JPY	6,000	0.21 (JPY:NTD)	1,235
EUR	17	35.77 (EUR:NTD)	606
<u>Financial liabilities</u>			
Monetary items			
JPY	9,438	0.21 (JPY:NTD)	1,942

December 31, 2024

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 97	32.79 (USD:NTD)	\$ 3,172
JPY	3,005	0.21 (JPY:NTD)	631
EUR	73	34.14 (EUR:NTD)	2,499
<u>Financial liabilities</u>			
Monetary items			
USD	107	32.79 (USD:NTD)	3,517
JPY	4,505	0.21 (JPY:NTD)	945
EUR	74	34.14 (EUR:NTD)	2,531

September 30, 2024

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 50	31.65 (USD:NTD)	\$ 1,597
EUR	115	35.38 (EUR:NTD)	4,071
<u>Financial liabilities</u>			
Monetary items			
USD	1	31.65 (USD:NTD)	45
EUR	136	35.38 (EUR:NTD)	4,824

Refer to Note 23 (h) for the foreign currency exchange gains and losses (realized and unrealized) of the Group for the nine months ended September 30, 2025 and 2024. Due to the wide variety of foreign currency transactions, it is impractical to disclose the exchange gains and losses for each foreign currency.

34. SEPARATELY DISCLOSED ITEMS

a. Information on significant transactions:

- 1) Financing provided to others: None;
- 2) Endorsements/guarantees provided: None;
- 3) Significant marketable securities held (excluding investments in subsidiaries and associates): (Table 1);
- 4) Total purchases from or sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital: None;
- 5) Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital: None;
- 6) Others: Intercompany relationships and significant intercompany transactions: (Table 4)

b. Information on investees (Table 2)

c. Information on investments in mainland China

- 1) Information on any investee company in mainland China, showing the name, principal business activities, paid-in capital, method of investment, inward and outward remittance of funds, ownership percentage, investment income or loss, carrying amount of the investment at the end of the period, repatriations of investment income, and limit on the amount of investment in the mainland China area (Table 3)
- 2) Any of the following significant transactions with investee companies in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses:
 - a) The amount and percentage of purchases and the balance and percentage of the related payables at the end of the year: None;

- b) The amount and percentage of sales and the balance and percentage of the related receivables at the end of the year: Table 3
- c) The amount of property transactions and the amount of the resultant gains or losses: None;
- d) The balance of negotiable instrument endorsements or guarantees or pledges of collateral at the end of the year and the purposes: None;
- e) The highest balance, the ending balance, the interest rate range, and total current period interest with respect to the financing of funds: None;
- f) Other transactions that have a material effect on the profit or loss for the year or on the financial position, such as the rendering or receipt of services: None;

35. SEGMENT INFORMATION

Information reported to the Group's chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the type of goods or services delivered or provided. The reporting departments of the Group are as follows: Management Department, Consumer Business Department, and Pharmaceutical Business Department.

a. Segment revenue and results

The following was an analysis of the Group's revenue and results from continuing operations by reportable segments:

	Segment Income		Segment Gain/Loss	
	For the Nine Months Ended September 30		For the Nine Months Ended September 30	
	2025	2024	2025	2024
Consumer business unit	\$ 819,908	\$ 780,571	\$ 148,438	\$ 164,209
Pharmaceutical business unit	<u>349,332</u>	<u>329,208</u>	<u>95,921</u>	<u>80,683</u>
	<u>\$ 1,169,240</u>	<u>\$ 1,109,779</u>	244,359	244,892
Inseparable management expense			(67,768)	(74,238)
Interest income			5,936	6,187
Rental income			8,174	8,440
Dividend income			8,880	7,682
Other income			1,150	2,321
Gain on financial assets at fair value through profit or loss			281	60
Foreign exchange gains			978	529
Gain on lease modification			6	-
Interest expenses			(6,071)	(1,271)
Share of loss of associates			<u>(12,519)</u>	<u>(14,233)</u>
Profit before taxes (continuing operations)			<u>\$ 183,406</u>	<u>\$ 180,369</u>

Segment revenue reported above represents revenue generated from external customers. There were no intersegment sales for the nine months ended September 30, 2025 and 2024.

Segment profit represented the profit before tax earned by each segment without interest income, rental income, dividend income, other income, gain of financial assets at fair value through profit or loss, foreign currency exchange gains, gain on lease modification, interest expense and share of loss associates. This measured amount was reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance.

b. Segment assets

The Group had not reported segment assets and liabilities information to the chief operating decision maker. Thus, no disclosure is made.

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

SIGNIFICANT MARKETABLE SECURITIES HELD (EXCLUDING INVESTMENTS IN SUBSIDIARIES)

SEPTEMBER 30, 2025

(Amounts in Thousands of New Taiwan Dollars)

Holding Company Name	Marketable Securities Type and Name	Relationship with the Company	Financial Statement Account	September 30, 2025				Note
				Shares/Units (In Thousands)	Carrying Amount	Percentage of Ownership (%)	Fair Value (Note 1)	
Maywufa Company Ltd.	<u>Share</u>							
	Cathay Financial Holdings Co., Ltd.	-	Financial assets at fair value through other comprehensive income	253	\$ 16,594	-	\$ 16,594	Listed shares
	Fubon Financial Holding Co., Ltd.	-	Financial assets at fair value through other comprehensive income	86	7,612	-	7,612	Listed shares
	Taiwan Incubator SME Development Corp.	Same chairman	Financial assets at fair value through other comprehensive income	8,526	73,819	12.08	73,819	
	Miho International Cosmetic Co., Ltd.	-	Financial assets at fair value through other comprehensive income	333	-	0.39	-	
	Career Consulting Co., Ltd.	-	Financial assets at fair value through other comprehensive income	505	7,742	3.23	7,742	
	Amersen Bioscience International, Inc.	-	Financial assets at fair value through other comprehensive income	568	-	8.43	-	
	Biowell Technology, Inc.	-	Financial assets at fair value through other comprehensive income	3,272	-	7.56	-	
	WS Fashion Group Co., Ltd.	-	Financial assets at fair value through other comprehensive income	13	230	0.38	230	
Amkey Biotechnology Venture Capital Inc.	-	Financial assets at fair value through other comprehensive income	147	6,284	6.66	6,284		
					<u>\$ 112,281</u>			

Note 1: Reference of fair value: listed (over the counter) stocks of financial assets measured by fair value through other comprehensive income are the closing prices at the end of September 2025, and unlisted (over the counter) stocks are estimated market prices based on the fair value evaluation method.

Note 2: For information of subsidiaries, refer to Tables 2 and 3.

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

INFORMATION ON INVESTEEES

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025

(Amounts in Thousands of New Taiwan Dollars and U.S. Dollars, Unless Specified Otherwise)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of September 30, 2025			Net Income (Loss) of the Investee	Share of Profit (Loss) (Note 1)	Note
				September 30, 2025	December 31, 2024	Shares (In Thousands)	%	Carrying Amount			
Maywufa Company Ltd.	<u>Related company</u> PhytoHealth Corporation	Fuxing N. Rd., Taipei City, Taiwan (R.O.C.)	Pharmaceutical research and development, production, manufacturing and sales	\$ 1,028,697	\$ 1,016,963	36,020	18.14	\$ 453,127	\$ (41,159)	\$ (7,995)	Dissolution and liquidation
	AmCad BioMed Corporation	Fuxing N. Rd., Taipei City, Taiwan (R.O.C.)	Medical materials and equipment manufacturing	77,737	77,737	3,995	6.31	33,021	(41,661)	(2,612)	
	Broadsound Corporation	Xintai Rd., Zhubei City, Taiwan (R.O.C.)	Medical materials and equipment manufacturing	26,360	26,360	2,019	10.00	20,960	(17,075)	(1,926)	
	Lu Te Na Company Limited	Fuxing N. Rd., Taipei City, Taiwan (R.O.C.)	Cosmetics sales	7,000	7,000	700	35.00	2,343	39	14	
	<u>Subsidiaries</u> Maywufa Corporation	Vistra Corporate Services Centre, Ground Floor NPF Building, Beach Road, Apia, Samoa	Investment	US\$ 8,500	US\$ 8,500	8,500	100.00	131,063	(3,565)	(3,565)	(Note 2)
Maywufa Corporation	Maywufa Hongkong Corporation Limited	Room 06, G/F, 535 Canton Road, Kowloon, Hong Kong	Investment	US\$ 8,500	US\$ 8,500	8,500	100.00	131,867	(3,565)	(3,565)	(Note 2)
Maywufa Hongkong Corporation Limited	Maywufa Cosmetics (Shanghai) Co., Ltd.	Room 902, No. 777, Hongqiao Road, Xuhui District, Shanghai	Cosmetics and household goods wholesale	US\$ 7,500	US\$ 7,500	-	100.00	131,864	(3,565)	(3,565)	(Note 2)

Note 1: Recognition of investment gains (losses) was based on the investee's reviewed financial statements.

Note 2: The amounts have been eliminated from the consolidated financial statements.

Note 3: For the information on investment in mainland China, refer to Table 3.

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

INFORMATION ON INVESTMENTS IN MAINLAND CHINA
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025
(Amounts in Thousands of New Taiwan Dollars and US Dollars)

1. Name of the investee company in mainland China, main businesses, paid-in capital, investment method, capital remittance, shareholding ratio, investment profit and loss, book value of investment at the end of the period, and repatriated investment profit and loss were as follow:

Investee Company	Main Businesses and Products	Paid-in Capital	Method of Investment	Accumulated Outward Remittance for Investment from Taiwan as of January 1, 2025	Remittance of Funds		Accumulated Outward Remittance for Investment from Taiwan as of September 30, 2025	Net Income (Loss) of the Investee	% Ownership of Direct or Indirect Investment	Accumulated Repatriation of Investment Income as of September 30, 2025	Carrying Amount as of September 30, 2025	Accumulated Inward Remittance for Investment from Taiwan as of September 30, 2025
					Outward	Inward						
Maywufa Cosmetics (Shanghai) Co., Ltd.	Cosmetics and household goods wholesale	\$ 226,459 (US\$ 7,500)	Reinvesting in mainland China through companies located in a third region (Note 1)	\$ 226,459 (US\$ 7,500)	\$ -	\$ -	\$ 226,459 (US\$ 7,500)	\$ (3,565)	100	\$ (3,565) (Note 2)	\$ 131,864	\$ -

Note 1: The Company located in a third region is Maywufa Hongkong Corporation Limited.

Note 2: Investment gains and losses are recognized according to the financial statements reviewed by the accountant.

2. Investment limit in mainland China

(Amounts in Thousands of New Taiwan Dollars and US Dollars)

Accumulated Outward Remittance for Investments in Mainland China as of September 30, 2025	Investment Amount Authorized by the Investment Commission, MOEA	Upper Limit on the Amount of Investments Stipulated by the Investment Commission, MOEA
\$226,459 (US\$7,500)	\$334,895 (US\$11,000)	\$1,250,743

Note: Upper Limit on the Amount of Investments Stipulated by the Investment Commission, MOEA = \$2,084,572 × 60% = \$1,250,743.

3. The significant transactions with investee companies in mainland China either directly or indirectly through a third party.

Investee Company	Relationship with the Company	Transaction Type	Price	Transaction Details			Notes/Accounts Receivable (Payable)		Unrealized Gain (Loss)
				Price	Payment Terms	Comparison with Normal Transactions	Ending Balance	%	
Maywufa Cosmetics (Shanghai) Co., Ltd.	Subsidiary	Sales revenue	\$ 12,758	Determined by contract or negotiation	The credit period for hairdressing products is 3 months	Similar to general transaction	\$ 1,408	-	\$ 805

4. Endorsements, guarantees or collateral provided to mainland investment companies directly or indirectly through companies in a third region: None.
5. Direct and indirect financing with mainland investment companies via third regions: None.
6. Other transactions that have a significant impact on the current profit or loss or financial position: None.
7. When preparing the consolidated financial statements, the above transactions have been eliminated.

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

**INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS
FOR NINE MONTHS ENDED SEPTEMBER 30, 2025
(Amounts in Thousands of New Taiwan Dollars)**

No.	Investee Company	Counterparty	Relationship	Transactions Details			
				Financial Statement Account	Amount (Note 1)	Payment Terms	% of Total Sales or Assets (Note 2)
0	Maywufa Company Ltd.	Maywufa Cosmetics (Shanghai) Co., Ltd.	Parent company to subsidiary	Operating income Accounts receivable	\$ 12,758 1,408	Similar to general transaction The credit period for hairdressing products is 3 months	1 -

Note 1: The table only shows one-way transactions, and the transactions have been eliminated.

Note 2: The calculation of the ratio of the transaction amount to the consolidated total revenue or total assets: If it is an asset - liability account, it is calculated as the ending balance of the consolidated total assets; if it is a profit and loss account, it is calculated as the cumulative amount to the consolidated total revenue.